Top Stories
The FDA accepted a filing for deucrictibant IR and has set a decision deadline of April 23, 2027.
The collaboration focuses on small-molecule breast cancer therapies developed using Astex Pharmaceuticals' fragment-based drug discovery platform.
The deal adds Myricx Bio's NMT inhibitor payload platform and two solid tumour ADC assets to Novartis' pipeline.
As part of the conditional marketing authorisation, the MHRA will review new information on the GLP-1 drug at least every year.
Nature Medicine study suggests transcriptomics-based model could improve patient selection.
Conference News
Recently, the final survival analysis of the Phase 3 ASTRUM-002 study involving serplulimab, Henlius’ self-developed anti-PD-1 monoclonal antibody (mAb), as first-line treatment for advanced non-squam...
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent s...
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain at...
Fully enrolled 123-patient Phase 1b cohort demonstrated 21.2-month median overall survival, 33% three-year overall survival, and a survival curve plateau beyond two yearsData presented in a heavily pr...
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
